ArticleEsophagus : official journal of the Japan Esophageal Society2026
Real-world treatments and outcomes in metastatic and recurrent esophageal squamous cell carcinoma in Japan: a retrospective analysis using the Millennial Medical Record database.
Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) remains a significant clinical challenge in Japan. Real-world data on treatment patterns and outcomes, particularly for patients unfit for cisplatin, remain limited. This study evaluated characteristics, treatments, and outcomes of patients newly diagnosed with metastatic ESCC (mESCC) or recurrent ESCC (rESCC).
methodsA retrospective cohort analysis was conducted using the Millennial Medical Record database (December 2021-June 2024), including patients with m/rESCC. Patients receiving first-line (1 L) systemic therapy were categorized into cisplatin or non-cisplatin groups. Key outcomes included time-to-treatment discontinuation and overall survival (OS).
resultsAmong 155 patients, 52.3% had mESCC and 47.7% had rESCC; 31.0% received 1 L systemic therapy, 46.4% underwent surgery or radiotherapy, and 22.6% received no treatment. Among those receiving 1 L therapy, 58.3% were treated with immune checkpoint inhibitors (ICIs), either in combination with chemotherapy or alone. Non-cisplatin patients were older with greater comorbidity burden; ~33.3% receiving ICI monotherapy and 27.8% dual ICI therapy. In contrast, 56.7% of patients in the cisplatin group received a cisplatin-ICI combination. Treatment discontinuation was more frequent with cisplatin than non-cisplatin therapy (73.3% vs. 55.6%), despite longer median treatment duration (75 vs. 47 days). Twelve-month OS was higher with cisplatin than non‑cisplatin regimens (92.1% vs. 75.0%).
conclusionsIn this real-world Japanese study, cisplatin-based regimens were commonly used for m/rESCC. Many patients who did not receive cisplatin had differing outcomes. This highlights the unmet need for better-tolerated alternatives for cisplatin-unfit patients with ESCC in Japan.
Indexed as
Identifiers
42474875What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.